{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:50:50Z","timestamp":1754160650797,"version":"3.41.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,26]]},"DOI":"10.7759\/cureus.88829","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T03:23:05Z","timestamp":1753586585000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Serological Profile of Myasthenia Gravis in the O\u2019Higgins Region of Chile: A Regional Study"],"prefix":"10.7759","author":[{"given":"Manuel","family":"Orellana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Maraga\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.04.006","article-title":"Myasthenia gravis. Update on diagnosis and therapy","volume":"161","author":"Garc\u00eda Est\u00e9vez DA","year":"2023","unstructured":"Garc\u00eda Est\u00e9vez DA, Pardo Fern\u00e1ndez J. Myasthenia gravis. Update on diagnosis and therapy. Med Clin (Barc). 2023, 161:119-27. 10.1016\/j.medcli.2023.04.006","journal-title":"Med Clin (Barc)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.07.006","article-title":"Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis","volume":"29","author":"de Meel RH","year":"2019","unstructured":"de Meel RH, Tannemaat MR, Verschuuren JJ. Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis. Neuromuscul Disord. 2019, 29:664-70. 10.1016\/j.nmd.2019.07.006","journal-title":"Neuromuscul Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami P","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al.. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021, 96:114-22. 10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.sedeng.2024.05.001","article-title":"Social support, quality of life and activities of daily living in patients with myasthenia gravis in Spain and Latin","volume":"59","author":"Larrosa-Dominguez M","year":"2024","unstructured":"Larrosa-Dominguez M, Revert\u00e9-Villarroya S. Social support, quality of life and activities of daily living in patients with myasthenia gravis in Spain and Latin. Rev Cient Soc Enferm Neurol (English ed.). 2024, 59:9-18. 10.1016\/j.sedeng.2024.05.001","journal-title":"Rev Cient Soc Enferm Neurol (English ed.)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga AR","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM, et al.. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022, 21:176-88. 10.1016\/s1474-4422(21)00297-0","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12967","article-title":"Clinical and epidemiological features of myasthenia gravis in Chilean population","volume":"138","author":"Cea G","year":"2018","unstructured":"Cea G, Martinez D, Salinas R, Vidal C, Hoffmeister L, Stuardo A. Clinical and epidemiological features of myasthenia gravis in Chilean population. Acta Neurol Scand. 2018, 138:338-43. 10.1111\/ane.12967","journal-title":"Acta Neurol Scand"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4135\/9781412953948.n53","article-title":"Capture-recapture method","author":"Adams AL","year":"2008","unstructured":"Adams AL. Capture-recapture method. Encyclopedia of Epidemiology. Boslaugh S (ed): Sage Publications, Inc.,  Los Angeles, CA; 2008. 10.4135\/9781412953948.n53"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmclc.2018.09.003","article-title":"Neuromuscular disorders. Epidemiology and health policies in Chile [Article in Spanish]","volume":"29","author":"Castiglioni C","year":"2018","unstructured":"Castiglioni C, Jofr\u00e9 J, Su\u00e1rez B. Neuromuscular disorders. Epidemiology and health policies in Chile [Article in Spanish]. Rev M\u00e9d Cl\u00edn Las Condes . 2018, 29:594-8. 10.1016\/j.rmclc.2018.09.003","journal-title":"Rev M\u00e9d Cl\u00edn Las Condes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30154-5","article-title":"The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis","volume":"13","author":"Tomschik M","year":"2023","unstructured":"Tomschik M, Renaud E, J\u00e4ger F, et al.. The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis. Sci Rep. 2023, 13:2985. 10.1038\/s41598-023-30154-5","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semerg.2018.01.003","article-title":"An update on myasthenia gravis [Article in Spanish]","volume":"44","author":"Mart\u00ednez Torre S","year":"2018","unstructured":"Mart\u00ednez Torre S, G\u00f3mez Molinero I, Mart\u00ednez Gir\u00f3n R. An update on myasthenia gravis [Article in Spanish]. Semergen. 2018, 44:351-4. 10.1016\/j.semerg.2018.01.003","journal-title":"Semergen"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.78058","article-title":"Single-fiber EMG: a review","volume":"14","author":"Selvan VA","year":"2011","unstructured":"Selvan VA. Single-fiber EMG: a review. Ann Indian Acad Neurol. 2011, 14:64-7. 10.4103\/0972-2327.78058","journal-title":"Ann Indian Acad Neurol"},{"key":"ref12","unstructured":"Mayo Clinics Laboratories. Muscle-Specific Kinase (MuSK) autoantibody serum. (2025). Accessed: April 1, 2025: https:\/\/www.mayocliniclabs.com\/test-catalog\/overview\/64277."},{"key":"ref13","unstructured":"Mayo Clinic Laboratories. Acetylcholine Receptor (muscle AChR) serum. (2025). Accessed: April 1, 2025: https:\/\/www.mayocliniclabs.com\/test-catalog\/overview\/8338."},{"key":"ref14","unstructured":"Instituto Nacional de Estad\u00edsticas. 2024 Population and Housing Census (INE), National Government of Chile [Website in Spanish]. (2025). Accessed: April 1, 2025: https:\/\/censo2024.ine.gob.cl\/resultados\/."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000477733","article-title":"Incidence of autoimmune myasthenia gravis in a health maintenance organization in Buenos Aires, Argentina","volume":"48","author":"Bettini M","year":"2017","unstructured":"Bettini M, Chaves M, Cristiano E, Pagotto V, Perez L, Giunta D, Rugiero M. Incidence of autoimmune myasthenia gravis in a health maintenance organization in Buenos Aires, Argentina. Neuroepidemiology. 2017, 48:119-23. 10.1159\/000477733","journal-title":"Neuroepidemiology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.33588\/rn.7602.2021201","article-title":"Epidemiology of myasthenia gravis in the Iberian Peninsula and Latin America [Article in Spanish]","volume":"76","author":"Garc\u00eda-Est\u00e9vez DA","year":"2023","unstructured":"Garc\u00eda-Est\u00e9vez DA, Fraga-Bau A, Garc\u00eda-Sobrino T, Mederer-Hengstl S, Pardo-Fern\u00e1ndez J. Epidemiology of myasthenia gravis in the Iberian Peninsula and Latin America [Article in Spanish]. Rev Neurol. 2023, 76:59-68. 10.33588\/rn.7602.2021201","journal-title":"Rev Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-017-2840-1","article-title":"A first description of the Colombian national registry for rare diseases","volume":"10","author":"Mateus HE","year":"2017","unstructured":"Mateus HE, P\u00e9rez AM, Mesa ML, et al.. A first description of the Colombian national registry for rare diseases. BMC Res Notes. 2017, 10:514. 10.1186\/s13104-017-2840-1","journal-title":"BMC Res Notes"},{"key":"ref18","article-title":"Epidemiologic study of myasthenia in Uruguay [Article in Spanish]","volume":"21","author":"Deff\u00e9minis Rospide HA","year":"1975","unstructured":"Deff\u00e9minis Rospide HA, Pietra de Mirabal M, Piazza de Silva N, Vincent O, M\u00e9dici M, Scarabino R. Epidemiologic study of myasthenia in Uruguay [Article in Spanish]. Acta Neurol Latinoam. 1975, 21:53-65.","journal-title":"Acta Neurol Latinoam"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2024.02.392","article-title":"Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data","volume":"180","author":"Keovilayhong S","year":"2024","unstructured":"Keovilayhong S, Mulliez A, Feral L, et al.. Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data. Rev Neurol (Paris). 2024, 180:451-8. 10.1016\/j.neurol.2024.02.392","journal-title":"Rev Neurol (Paris)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-823912-4.00026-8","article-title":"Myasthenia gravis-pathophysiology, diagnosis, and treatment","volume":"200","author":"Tannemaat MR","year":"2024","unstructured":"Tannemaat MR, Huijbers MG, Verschuuren JJ. Myasthenia gravis-pathophysiology, diagnosis, and treatment. Handb Clin Neurol. 2024, 200:283-305. 10.1016\/B978-0-12-823912-4.00026-8","journal-title":"Handb Clin Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli A","year":"2018","unstructured":"Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, Marino M. Myasthenia gravis with antibodies to MuSK: an update. Ann NY Acad Sci. 2018, 1412:82-9. 10.1111\/nyas.13518","journal-title":"Ann NY Acad Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13091286","article-title":"Diagnosis and management of seronegative myasthenia gravis: lights and shadows","volume":"13","author":"Vinciguerra C","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Lupica A, et al.. Diagnosis and management of seronegative myasthenia gravis: lights and shadows. Brain Sci. 2023, 13:1286. 10.3390\/brainsci13091286","journal-title":"Brain Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz PM","year":"2015","unstructured":"Rodr\u00edguez Cruz PM, Al-Hajjar M, Huda S, et al.. Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol. 2015, 72:642-9. 10.1001\/jamaneurol.2015.0203","journal-title":"JAMA Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22078-3\u00a0","article-title":"Mental health in myasthenia gravis patients and its impact on caregiver burden","volume":"12","author":"Marbin D","year":"2022","unstructured":"Marbin D, Piper SK, Lehnerer S, Harms U, Meisel A. Mental health in myasthenia gravis patients and its impact on caregiver burden. Sci Rep. 2022, 12:19275. 10.1038\/s41598-022-22078-3\u00a0","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06927-1","article-title":"Alterations in short-term blood pressure variability related to disease severity and autonomic symptoms in myasthenia gravis patients","volume":"44","author":"Zawadka-Kunikowska M","year":"2023","unstructured":"Zawadka-Kunikowska M, Rzepi\u0144ski \u0141, Cie\u015blicka M, Klawe JJ, Tafil-Klawe M. Alterations in short-term blood pressure variability related to disease severity and autonomic symptoms in myasthenia gravis patients. Neurol Sci. 2023, 44:4065-75. 10.1007\/s10072-023-06927-1","journal-title":"Neurol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10248","article-title":"Myasthenia gravis and its association with thyroid diseases","volume":"12","author":"Amin S","year":"2020","unstructured":"Amin S, Aung M, Gandhi FR, Pena Escobar JA, Gulraiz A, Malik BH. Myasthenia gravis and its association with thyroid diseases. Cureus. 2020, 12:e10248. 10.7759\/cureus.10248","journal-title":"Cureus"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment","volume":"31","author":"Gilhus NE","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK, et al.. Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol. 2024, 31:e16229. 10.1111\/ene.16229","journal-title":"Eur J Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872020000701031","article-title":"Refractory myasthenia gravis with good response to rituximab. Report of one case [Article in Spanish]","volume":"148","author":"Su\u00e1rez H F","year":"2020","unstructured":"Su\u00e1rez H F, Urrutia E D. Refractory myasthenia gravis with good response to rituximab. Report of one case [Article in Spanish]. Rev Med Chil. 2020, 148:1031-3. 10.4067\/S0034-98872020000701031","journal-title":"Rev Med Chil"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001196","article-title":"Current drug treatment of myasthenia gravis","volume":"36","author":"Vanoli F","year":"2023","unstructured":"Vanoli F, Mantegazza R. Current drug treatment of myasthenia gravis. Curr Opin Neurol. 2023, 36:410-5. 10.1097\/WCO.0000000000001196","journal-title":"Curr Opin Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold C","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019, 12:1756286419832242. 10.1177\/1756286419832242","journal-title":"Ther Adv Neurol Disord"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1307627","article-title":"The burden of myasthenia gravis - highlighting the impact on family planning and the role of social support","volume":"14","author":"Stein M","year":"2023","unstructured":"Stein M, Grittner U, Stegherr R, et al.. The burden of myasthenia gravis - highlighting the impact on family planning and the role of social support. Front Neurol. 2023, 14:1307627. 10.3389\/fneur.2023.1307627","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/391351-clinical-and-serological-profile-of-myasthenia-gravis-in-the-ohiggins-region-of-chile-a-regional-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T03:23:10Z","timestamp":1753586590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/391351-clinical-and-serological-profile-of-myasthenia-gravis-in-the-ohiggins-region-of-chile-a-regional-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.88829","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,26]]}}}